Company Announcements

• Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022
• Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023
• Signed preferred stock purchase agreement with a potential strategic investor in October 2023
• Entered into a warrant inducement agreement with an institutional investor in October 2023
• Subsidiaries Curetis GmbH in Germany and Ares Genetics GmbH in Austria filed for insolvency under German and Austrian laws, respectively, in November 2023
  

ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.

Third Quarter 2023 Financial Results of OpGen, Inc.

• Total revenue for the third quarter of 2023 was approximately $0.70 million compared to the Company’s revenue of approximately $0.45 million in the third quarter of 2022. Total revenue for the nine months ended September 30, 2023 was approximately $2.35 million compared to the Company’s revenue of approximately $1.89 million in the nine months ended September 30, 2022.
• Total operating expenses decreased in the third quarter of 2023 to approximately $4.26 million compared to approximately $13.96 million for the third quarter of 2022 primarily due to the Company’s goodwill impairment charge of $6.98 million recorded in the third quarter of 2022. Total operating expenses decreased by approximately 39% in the nine months ended September 30, 2023 to approximately $16.14 million compared to approximately $26.52 million for the same period in 2022.
• Cash and cash equivalents were approximately $0.29 million as of September 30, 2023, compared with approximately $7.44 million as of December 31, 2022.
  

The Company entered into two agreements in October 2023 to improve its cash position consisting of a preferred stock purchase agreement for $1.0 million in gross proceeds with a potential strategic investor and a warrant inducement agreement with an existing institutional investor that, as of November 14, 2023, resulted in gross proceeds of approximately $2.06 million. Nevertheless, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company continues to actively consider multiple alternatives, including, but not limited to, restructuring or refinancing its debt, seeking additional debt or equity capital, reducing or delaying business activities, selling assets, other strategic financings or transactions and other measures, including obtaining relief under applicable bankruptcy laws. There can be no assurance that the Company will be able to identify or execute on any of these alternatives on acceptable terms or that any of these alternatives will be successful.

In the reporting quarter and year to date, the Company has seen the following key developments:

• OpGen implemented certain cash management initiatives, including restructuring its U.S. operations by reducing headcount from 23 to 6 and scaling down operations at OpGen’s U.S. headquarters to the core functions of a U.S. Nasdaq listed company with only minimal marketing and sales support, allowing the Company to conserve cash and focus on the functions needed to pursue potential strategic alternatives.
• In October 2023, OpGen amended its non-exclusive distribution agreement with Fisher Healthcare to allow Fisher Healthcare to sell to existing U.S. Unyvero customers of the Company, which had previously been maintained by the Company’s sales force.
• In October 2023, OpGen discontinued its FDA cleared Acuitas AMR Gene Panel diagnostic test.
• In October 2023, OpGen’s German subsidiary Curetis GmbH responded to all of the FDA’s additional requests with regard to Curetis' De Novo request for the Unyvero UTI urinary tract infection test in order to continue the FDA review.
• In October 2023, OpGen entered into a preferred stock purchase agreement with a potential strategic investor for gross proceeds of $1.0 million in exchange for 1,000 shares of the Company’s Series D Preferred Stock. In connection with the ongoing discussions for a transaction with such potential strategic investor, the parties anticipate closing the transaction under the preferred stock purchase agreement as soon as practical.
• On November 6, 2023, following OpGen’s unsuccessful efforts to sell the businesses or assets of its wholly owned subsidiaries Curetis GmbH and Ares Genetics GmbH or to access additional capital to continue their operations, Curetis GmbH and Ares Genetics GmbH filed for insolvency under the applicable German and Austrian laws, respectively.

About OpGen, Inc. 

OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, both of which are subject to insolvency proceedings under German and Austrian laws, respectively, since November 6, 2023, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud.

For more information, please visit www.opgen.com

Forward-Looking Statements

This press release includes statements regarding the third quarter of 2023 and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the risks and uncertainties relating to the insolvency proceedings of Curetis GmbH and Ares Genetics GmbH, our ability to continue to finance our business and operations, the result of any alternatives to mitigate the Company’s cash position, including restructuring or refinancing of our debt, seeking additional debt or equity capital, reducing or delaying our business activities, selling assets, other strategic transactions or other measures, including obtaining relief under U.S. bankruptcy laws, and the terms, value and timing of any transaction resulting from such alternatives, our ability to satisfy debt obligations under our loan with the European Investment Bank, and our liquidity and working capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Investor & Press Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com

OpGen, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (unaudited)
		September 30, 2023				December 31, 2022
Assets
Current assets
Cash and cash equivalents		$	292,642			$	7,440,030
Accounts receivable, net			422,725				514,372
Inventory, net			1,198,259				1,345,137
Prepaid expenses and other current assets			1,541,074				1,355,949
Total current assets			3,454,700				10,655,488
Property and equipment, net			3,820,829				3,457,531
Finance lease right-of-use assets, net			986				3,500
Operating lease right-of-use assets			1,915,049				1,459,413
Intangible assets, net			6,842,406				7,440,974
Strategic inventory			1,608,890				2,300,614
Other noncurrent assets			492,022				495,629
Total assets		$	18,134,882			$	25,813,149
Liabilities and Stockholders’ Equity
Current liabilities
Current maturities of long-term debt		$	9,199,764			$	7,023,901
Accounts payable			904,559				420,821
Accrued compensation and benefits			381,807				1,097,654
Accrued liabilities			1,268,723				1,526,204
Deferred revenue			194,687				142,061
Short-term finance lease liabilities			1,121				3,364
Short-term operating lease liabilities			521,424				377,626
Total current liabilities			12,472,085				10,591,631
Long-term debt, net			—				4,850,686
Derivative liabilities			34,364				99,498
Long-term finance lease liabilities			—				280
Long-term operating lease liabilities			2,830,282				2,566,138
Other long-term liabilities			121,428				129,368
Total liabilities			15,458,159				18,237,601
Stockholders’ equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2023 and December 31, 2022			—				—
Common stock, $0.01 par value; 100,000,000 shares authorized; 10,013,524 and 2,899,911 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively			100,135				28,999
Additional paid-in capital			291,705,905				281,167,161
Accumulated deficit			(288,451,655	)			(272,824,772	)
Accumulated other comprehensive loss			(677,662	)			(795,840	)
Total stockholders’ equity			2,676,723				7,575,548
Total liabilities and stockholders’ equity		$	18,134,882			$	25,813,149

OpGen, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
	Three months ended September 30,									Nine months ended September 30,
	2023				2022					2023					2022
Revenue
Product sales	$	558,965			$	359,112				$	1,409,534				$	1,614,435
Laboratory services		47,135				31,016					112,810					94,515
Collaboration revenue		92,922				58,585					826,257					176,713
Total revenue		699,022				448,713					2,348,601					1,885,663
Operating expenses
Cost of products sold		618,796				1,886,191					1,925,566					2,824,577
Cost of services		73,174				17,239					405,582					63,450
Research and development		1,201,865				2,031,113					4,403,488					6,621,310
General and administrative		2,034,628				2,020,452					6,883,588					6,779,773
Sales and marketing		336,184				1,031,496					2,522,471					3,252,277
Goodwill impairment charge		—				6,975,520					—					6,975,520
Total operating expenses		4,264,647				13,962,011					16,140,695					26,516,907
Operating loss		(3,565,625	)			(13,513,298		)			(13,792,094		)			(24,631,244		)
Other (expense) income
Interest and other income		24,977				11,174					86,301					28,147
Interest expense		(396,768	)			(569,306		)			(1,698,564		)			(2,618,799		)
Foreign currency transaction (losses) gains		(135,930	)			(51,547		)			(288,326		)			419,160
Change in fair value of derivative financial instruments		10,389				18,995					65,800					54,623
Total other expense		(497,332	)			(590,684		)			(1,834,789		)			(2,116,869		)
Loss before income taxes		(4,062,957	)			(14,103,982		)			(15,626,883		)			(26,748,113		)
Provision for income taxes		—				—					—					—
Net loss	$	(4,062,957	)		$	(14,103,982		)		$	(15,626,883		)		$	(26,748,113		)
Net loss available to common stockholders	$	(4,062,957	)		$	(14,103,982		)		$	(15,626,883		)		$	(26,748,113		)
Net loss per common share – basic and diluted	$	(0.46	)		$	(5.92		)		$	(2.38		)		$	(11.40		)
Weighted average shares outstanding – basic and diluted		8,778,152				2,382,848					6,565,853					2,345,794
Net loss	$	(4,062,957	)		$	(14,103,982		)		$	(15,626,883		)		$	(26,748,113		)
Other comprehensive income (loss) – foreign currency translation		78,815				(536,758		)			118,178					(2,247,749		)
Comprehensive loss	$	(3,984,142	)		$	(14,640,740		)		$	(15,508,705		)		$	(28,995,862		)